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In recent years, there has been an increasing awareness of the importance of stereochemistry in drug disposition, particularly as improving analytical technology enables us to determine enantiomer concentrations in biological matrices. Thus, the interaction of a chiral drug molecule with asymmetric macromolecules, such as hepatic metabolizing enzymes and plasma proteins, results in the formation of transient diastereomeric complexes which might lead to differences in drug disposition profiles. Thus, differences in the disposition of drug enantiomers usually result from differences in hepatic metabolism and plasma protein binding, since the processes of absorption, distribution and excretion would normally involve passive difhsion which would not be expected to be affected by drug chirality. In this overview, enantio-selective drug metabolism will be discussed, focusing mainly on oxidative reactions, believed to be mediated by the so-called mixed function oxidases, a family of isoenzymes of cytochrome P-450. Current views on the mechanism of oxidation and on the size and shape of the active site of the enzymes will be considered.
Binding to cytochrome P-450
The family of cytochromes P-450 are currently viewed as the major xenobiotic metabolizing enzymes. These oxidative enzymes are iron containing, the ferroporphyrin complex being present as in the haem molecule. The cytochromes P-450 are generally of low substrate selectivity and reaction rates are comparatively slow, being several orders of magnitude less than, for example, that mediated by carbonic anhydrase. The detailed mechanism by which oxygen is transferred to the substrate is unknown and the features of the active site that govern substrate binding, particularly in mammalian systems, are not well defined. However, the basic catalytic cycle associated with the oxidation requires initial binding of the substrate in a hydrophobic pocket in close proximity to the prosthetic haem group. The enzyme is reduced to the ferrous state followed by the binding and activation
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of molecular oxygen to a highly reactive electrophilic species which is transferred to the substrate, with regeneration of the enzyme. The current view is that enantio-selectivity in metabolism is generally governed by the chirality of the substrate-binding pocket and the active site rather than by any intrinsic feature of the catalytic mechanism. For example, White [ 13 has demonstrated with an elegant series of experiments on specifically deuterated phenylethane derivatives using a single rabbit isoenzyme, P-45OLM2, that stereospecificity is enforced by the surrounding protein tertiary structure and is not an inherent feature of the reaction mechanism.
Researchers in several laboratories are directing their efforts to attempting to define the topology of the active site of cytochrome P-450 to further the understanding of the three-dimensional interaction with drug substrates. A major breakthrough in recent years was the determination by Poulos et al. [Z] of the crystal structure of P-45OCa,, a bacterial mono-oxygenase which was crystallized containing its substrate, camphor, bound at the active site. The camphor molecule is buried in a lipophilic pocket just above the haem moiety in such an orientation that the exo-surface at C-5 could contact 'activated' oxygen for stereoselective hydroxylation. This appears to be a very rigid enzyme-substrate complex since the 5-exo-hydroxy derivative is the sole product in this system. Interestingly, two other alicyclic compounds, adamantanone and adamantane, are hydroxylated by P-450,, to single products which are isosteric with the camphor metabolite, suggesting that each molecule was attacked at a top6logically congruent position ( Fig. 1) . Subsequently, the crystal structures of cytochrome P-45OCa, complexes with some molecules containing aromatic nitrogen atoms have been determined [3] . For example, the complex with metyrapone, a pyridine derivative, has the molecule bound in a lipophilic domain in such a way that the pyridine nitrogen atom acts as a sixth ligand at the haem iron, thus perturbing the 0,-binding pocket which presumably, rationalizes the inhibition observed for metyrapone. Comparison of protein sequence alignments suggests a high degree of sequence similarity for the active site of P-45OCa, and mammalian mono-oxygenases. Ortiz de Montellano and co-workers [4] argues for a common topography near the 0,-binding pocket. He carried out an elegant series of experiments in which the prosthetic haem group of a rat cytochrome P-450 was alkylated by olefins and acetylenes. Pyrrole rings, A, C and D reacted, but not ring B. This suggests that the active site is sterically hindered over ring B and he concluded that the elongated perimeter of the protein domain is centred over the porphyrin in such a way that ring B is covered. Thus the topographical picture of the microsomal P-450-binding pocket and active site is envisaged to be remarkably similar to that found in the P-45OC, X-ray structure. As research continues, the consideration of the three-dimensional nature of both the drug molecule and the enzymebinding site may help us to predict the increasing number of enantio-selective drug metabolism reactions, mediated by enzymes which are normally considered to be of low substrate specificity.
Enantio-selectivity in substrate and products
The influence of substrate binding in the chiral hydrophobic pocket and active site of the enzyme on the enantio-specificity of drug metabolism is manifest in an increasing number of examples.
Kupfer [ 51 has shown in studies in man on the anticonvulsant mephenytoin that the proportion of the S-and R-enantiomers in the urinary excretion of drug metabolites is different. The 4-hydroxy derivative of the S-enantiomer is by far the most prominent metabolite, whereas the R-enantiomer tends to undergo N-demethylation. This enantioselectivity for product formation presumably derives from different modes of binding of the substrate molecule resulting in different target groups being in close proximity to the catalytic site.
Another example of this highly stereospecific binding is found in the metabolism of diphenylhydantoin. One of the phenyl rings is phydroxylated in a highly selective manner leading to >90% of the S-enantiomer metabolite in man [6] .
This reaction shows species differences in that the compound suffers m-hydroxylation in the dog to give the R-enantiomer metabolite predominantly [7] . Diphenylhydantoin is an example of a compound, termed prochiral, which acquires chirality through metabolic transformation (or any other enantio-selective process).
A further example of the spatial nature of molecules effecting substrate enantio-selectivity may be found in the hydroxylation by rat-liver microsomes of warfarin and phenprocoumon, two closely related anticoagulants. Each compound is hydroxylated at the equivalent position on an aromatic ring, with high but, surprisingly, opposite substrate enantio-selectivity, R-warfarin and Sphenprocoumon being the preferred substrates. This was eventually explained when Heimark and Trager [8] showed that R-warfarin binds to cytochrome P-450 as the cyclic hemiketal tautomer which is then a topographically equivalent conformation to that of S-phenprocoumon (Fig. 2) .
The major metabolic routes for warfarin are hydroxylation at the 7-position of the coumarin ring and reduction of the side-chain ketone group. Species differences in stereo-specificities of the isoenzymes are apparent, since the 7-hydroxylation is highly selective for the S-enantiomer in man and for the R-enantiomer in rat. However, reduction of the keto group to the alcohol is selective for the Renantiomer in both man and rat, while the new chiral centre bearing the hydroxyl group has the Sconfiguration.
Metabolic chiral inversion
A relatively rare, but potentially highly significant, stereo-selective metabolic reaction is the inversion of the chirality of one enantiomer to that of its optical antipode. This reaction has been bound largely in only one group of compounds, the 2-arylpropionic acids (the profens) which are used as non-steroidal anti-inflammatory agents.
These acids contain a chiral centre in the propionate side-chain and undergo a unidirectional metabolic inversion of the R-to the biologically active S-antipode. The reaction is thought to proceed via formation of an acyl coA ester with the R ( -)-acid, which inverts and is hydrolysed to give S( + )-acid; the initial ester formation is apparently not available to the S( + )-acid thus giving enantioselectivity [9] . The inversion reaction exhibits wide variability in extent and rate for different profens, as well as between species, which makes prediction to the human situation difficult. Although the bestdocumented examples of inversion are within the profen group of compounds, at least two other cases have been reported. Haloxyfop is currently being evaluated as a herbicide [ 101. The compound, a 2-aryloxy propionate is structurally similar to the 2-aryl propionates and the racemic compound has been shown to be rapidly and virtually completely converted into the R-enantiomer in the rat. Studies on the thalidomide analogue EM12 in the marmoset monkey [ l l ] have shown that both the R-and Senantiomer undergo up to 30% inversion. Since both isomers suffer similar fates, the inversion reaction in this case may be chemically rather than enzymically mediated.
Manifestations of substrate enan tio-selectivity
There are many reported cases of chiral compounds where the individual enantiomers are metabolized or cleared at different rates. In the case of some drugs, it has been observed that the apparent parameters of drug disposition exhibit bimodal distribution within a population. For example, a small proportion of people (about 5%) may metabolize a particular drug appreciably more slowly than the majority and this difference has been shown to be under genetic control, the particular cytochrome P-450 being absent in the case of the poor metabolizers. This phenomenon has also been observed in the case of drug enantiomers. The R( + )-enantiomer of the 8-blocker bufuralol undergoes 1-hydroxylation on the alkyl group, whereas the S( -)-isomer suffers predominantly 4-hydroxylation on the aromatic ring. Extensive metabolizers excrete much larger amounts of the 1'-hydroxy compound than poor metabolizers Volume 19 when given the R( + )-isomer, whereas poor metabolizers excrete approximately the same amount of the 1'-hydroxy derivative from either enantiomer [14] . This shows that the polymorphic pathway is selective for R( + )-bufuralol (the reaction is in fact under genetic control of the debrisoquinelsparteine oxidation phenotype). As stated earlier, the metabolism of the anticonvulsant mephenytoin exhibits enantio-selectivity. The rates of the enantio-selective transformations differ by approximately 100-fold in the majority of people taking the drug. However, the usually rapid 4-hydroxylation of the S-enantiomer, is not seen in about 5% of the population again owing to a genetic defect (not related to the debrisoquine phenotype). In these poor metabolizers, the S-enantiomer undergoes slow metabolism to the N-desmethyl compound, the product normally formed from the R-enantiomer [15] . The very large differences in oral clearances of the two enantiomers is one of the most striking examples of stereo-selective drug metabolism in man.
Concluding remarks
The binding of drug molecules at the active site of drug-metabolizing enzymes often leads to enantioselective discrimination in substrate and/or products. These stereochemical aspects of drug disposition are often complex, differences being observed between species, and, in human populations, in individual variability in rates of metabolism, which may be under genetic control; the stereochemical course of the metabolism of a racemic drug being currently largely unpredictable. Chiral metabolism is only one of the many factors to consider, along with, for example, relative biological potency and economic feasibility, in the decision to take a particular candidate or one of its isomers into the development process.
